David Veitch - Basilea Pharmaceutica Executive
| BPMUF Stock | USD 52.83 0.00 0.00% |
Executive
Mr. David Veitch was appointed Chief Executive Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd effective as of April 19, 2018. He has served as Chief Commercial Officer and Member of the Management Committee of Basilea Pharmaceutica Ltd since September 1, 2014. Mr. Veitch served as the President of European Operations at Savient Pharmaceuticals from 2012 to 2013. From 2007 to 2011, he served as Senior Vice President of European Marketing Brand Commercialization at BristolMyers Squibb Pharmaceuticals. From 2004 to 2007, he was Vice President and General Manager UK at Bristol Myers Squibb Pharmaceuticals. Prior to this Mr. Veitch held various general management and commercial roles in BristolMyers Squibb Pharmaceuticals and prior to that with SmithKline Beecham Pharmaceuticals. Mr. Veitch received a B.Sc. in Biology from the University of Bristol. since 2018.
| Age | 58 |
| Tenure | 7 years |
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Myriam MD | CureVac NV | 59 | |
| Melanie MBA | Moderna | N/A | |
| Muthiah Manoharan | Alnylam Pharmaceuticals | 71 | |
| Shannon JD | Moderna | 54 | |
| Joaquim Marques | Ginkgo Bioworks Holdings | N/A | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| Adam Townsend | Apellis Pharmaceuticals | 47 | |
| Ulrike MD | CureVac NV | 52 | |
| Brad Miller | Moderna | 51 | |
| Andrew Elnatan | Sellas Life Sciences | N/A | |
| Lisa Birringer | BioNTech SE | N/A | |
| Said Saim | Eyepoint Pharmaceuticals | 66 | |
| James JD | Crispr Therapeutics AG | 53 | |
| Timothy Maines | Alnylam Pharmaceuticals | N/A | |
| Susan Kim | Crispr Therapeutics AG | N/A | |
| Charbel MPH | Moderna | N/A | |
| Ron Esq | Eyepoint Pharmaceuticals | N/A | |
| Dave Johnson | Moderna | N/A | |
| Sarah Kiely | ProQR Therapeutics BV | N/A | |
| Julianne MBA | Crispr Therapeutics AG | N/A | |
| Anna MBA | Ginkgo Bioworks Holdings | 35 | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lutz Wevelsiep, Head Affairs | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| David Veitch, Chief Commercial Officer, Member of the Management Committee | ||
| Ursula Eberhardt, Head HR | ||
| Marc MD, Chief Officer | ||
| Peer Schroder, Head Relations | ||
| Dietrich Stber, Head Services | ||
| Laurenz Kellenberger, Chief Scientific Officer |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.